Christopher Haddad, MD
Cardiovascular Disease · San Angelo, TXNPI 1912987264
Payments from drug & device makers
Across 723 payments — averaging $30.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$7K
- Abbott$4K
- Medtronic$2K
- AstraZeneca$2K
- Abiomed$2K
- Johnson & Johnson$595
- plus $4K from 25 others
What the payments were for
- Speaking & faculty fees$6,00027%
- Food & beverage$15,63271%
- Education$2401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 71 | $7,258 |
| Abbott | 179 | $4,317 |
| Medtronic(2 entities) | 78 | $1,858 |
| AstraZeneca | 76 | $1,830 |
| Abiomed | 83 | $1,707 |
| Johnson & Johnson | 44 | $595 |
| Heartflow, Inc. | 6 | $531 |
| E.r. Squibb & Sons, L.L.C. | 40 | $510 |
| Novartis | 23 | $457 |
| Edwards Lifesciences | 9 | $393 |
| Penumbra, Inc. | 4 | $345 |
| Cardiovascular Systems Inc. | 13 | $318 |
| Amarin Pharma, Inc. | 20 | $291 |
| Shockwave Medical, Inc | 3 | $203 |
| Merck | 9 | $151 |
| Amgen | 8 | $135 |
| Cook Medical LLC | 15 | $134 |
| Acist Medical Systems, Inc. | 3 | $133 |
| Boston Scientific | 6 | $116 |
| Novo Nordisk | 6 | $106 |
| Kowa Pharmaceuticals America, Inc. | 5 | $85 |
| Inari Medical, Inc. | 4 | $82 |
| Pfizer | 4 | $65 |
| Boehringer Ingelheim | 3 | $47 |
| Terumo Medical Corporation | 2 | $46 |
| Cordis US CORP. | 2 | $45 |
| Sanofi-aventis U.S. LLC | 3 | $42 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $30 |
| Vital Connect, Inc | 1 | $26 |
| Bard Peripheral Vascular, Inc. | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,891 in reported general payments places this provider in the 80th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 515 | $546,131 |
| EntrestoSacubitril/Valsartan | 220 | $221,810 |
| Repatha SureclickEvolocumab | 228 | $219,526 |
| BrilintaTicagrelor | 216 | $166,487 |
| XareltoRivaroxaban | 171 | $160,906 |
| FarxigaDapagliflozin Propanediol | 96 | $96,217 |
| VascepaIcosapent Ethyl | 66 | $50,073 |
| Repatha SyringeEvolocumab | 28 | $27,065 |
| Praluent PenAlirocumab | 36 | $24,349 |
| Ranolazine ErRanolazine | 307 | $24,149 |
| Atorvastatin Calcium | 1,198 | $11,291 |
| OzempicSemaglutide | 13 | $10,357 |
| JardianceEmpagliflozin | 13 | $10,234 |
| ClopidogrelClopidogrel Bisulfate | 812 | $9,225 |
| Potassium Chloride | 485 | $9,075 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $65 | $546,131515 claims |
| AstraZenecaBrilinta, Farxiga | $1,830 | $262,704312 claims |
| NovartisEntresto | $457 | $221,810220 claims |
| Johnson & JohnsonXarelto | $595 | $160,906171 claims |
| Novo NordiskOzempic | $106 | $10,35713 claims |
| Boehringer IngelheimJardiance | $47 | $10,23413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in San Angelo
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.